Section 32
About Section 32
Section 32 is a venture capital fund that invests at the cutting edge of technology, healthcare, and life sciences.
Investment focus
Stages
Sectors
Portfolio (24 in our database)
MOMA TherapeuticsMOMA Therapeutics operates as a biotechnology company.Series B · $236M raisedArbor BiotechnologiesArbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.Series B · $231M raisedAspen NeuroscienceAspen Neuroscience is a biotechnology company that uses innovative genomic approaches combined with stem cell biology.Series B · $224M raisedPrimerPrimer develops a text analytics solution designed to automate the analysis of textual data.Series C · $168M raisedCelsius TherapeuticsCelsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.Series B · $148M raisedVerge GenomicsVerge Genomics uses machine learning and human genomics to accelerate drug discovery.Series B · $134M raisedROME TherapeuticsROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.Series B · $127M raisedNeocisNeocis develops robot-assisted dental implant surgery with the aim of transforming dental surgery using advanced robotics.Series D · $123M raisedVinetiVineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.Series C · $115M raisedC2i GenomicsC2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations.Series B · $112M raisedCulture BiosciencesCulture Biosciences develops automated bio-reactors that help companies optimize their manufacturing processes.Series B · $102M raisedSatellite BioSatellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering.Series A · $101M raisedEmbarkEmbark offers dog DNA testing that ends preventable diseases in dogs.Series B · $94M raisedCurrent HealthWe help healthcare reduce risk & cost by monitoring, managing and engaging patients at home.Acquired · $92M raisedSyllableSyllable uses AI to transform the way healthcare systems initiate and cultivate relationships with patients.Series C · $82M raisedTwinStrand BiosciencesTwinStrand Biosciences develops and commercializes the duplex sequencing technology for DNA sequencing.Series B · $73M raisedWise SystemsWise Systems' autonomous dispatch and routing software uses AI to improve fleet efficiency and customer service for last-mile operations.Series C · $73M raisedGretelGretel helps developers to build quickly with the data and safely share it with others.Series B · $68M raisedExai BioExai Bio is a next-generation Orphan non-coding RNAs and AI based liquid biospy company.Series A · $68M raisedMiroculusMiroculus is a hands off sample-to-answer solution for molecular testing.Series B · $65M raisedWithMe HealthA medication guidance company personalizing medication experiences for employers, employees and their familiesSeries B · $45M raisedMekonosMekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip.Series A · $31M raisedMedArriveMedArrive is a startup that connects a workforce of EMS professionals to patients from their homes and within their existing health systems.Series B · $30M raisedCharacter BiosciencesBiopharmaceutical research and development companySeries A · $27M raised